C6 Ceramide
Based on 3 publication(s) in Google Scholar
C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.82%
- CAS 番号: 124753-97-5
- 分子式: C24H47NO3
- 分子量:397.63
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Anti-Cancer Compound Library
HY-L025
-
Lipid Compound Library
HY-L043
-
Anti-Blood Cancer Compound Library
HY-L079
-
Chemotherapy Drug Library
HY-L112
-
Cell Death Library
HY-L162
-
Anti-Drug-Resistant Compound Library
HY-L169
-
Anti-Hematopathy Compound Library
HY-L171
-
Immunopotentiator Compound Library
HY-L172
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
MedChemExpress（MCE）の使用を引用している文献 C6 Ceramide
More
Customer Validation & Images
-
ELISA
-
Cell Proliferation/Viability Assay
-
WB
-
Cell Imaging/Staining
-
Bio/Physico-chemical Assay
生物活性
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
35 μM
Compound: C6-Cer
|
Cytotoxicity against human A549 cells after 72 hrs by MTT test
Cytotoxicity against human A549 cells after 72 hrs by MTT test
|
[PMID: 17081760] |
| MCF7 | IC50 |
12 μM
Compound: C6Cer
|
Antiproliferative activity against human MCF7 cells after 24 hrs by trypan blue exclusion assay
Antiproliferative activity against human MCF7 cells after 24 hrs by trypan blue exclusion assay
|
[PMID: 20851613] |
| SUP-T1 | IC50 |
48.01 μM
Compound: C6 ceramide
|
Cytotoxicity against human SupT1 cells after 24 hrs by CellTiter-Blue assay
Cytotoxicity against human SupT1 cells after 24 hrs by CellTiter-Blue assay
|
[PMID: 19171486] |
C6 Ceramide (10 μg/mL, 48 h) enhances Trichostatin A (TSA) (HY-15144)-induced cell death, cell Apoptosis and induces a-tubulin acetylation in both CaOV3 and L3.6 cancer cells[1].
C6 Ceramide (10 μg/mL, 12 h) disrupts HDAC6/PP1/tubulin complex, leading to the release of PP1 and AKT dephosphorylation and inhibition in CaOV3 and L3.6 cancer cells [1].
C6 Ceramide (10 μM, 48 h) increases the expression of miR29b and decreases the expressions of Akt3, PI3K and VEGFA in HUVECs[2].
C6 Ceramide (3 and 10 μM, 7 days) increases the number of viable hippocampal neurons and enhances the dendritic outgrowth of neurons in vitro[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CaOV3 and L3.6 cancer cells
-
Concentration:10 μg/mL
-
Incubation Time:48 h
-
Result:Had almost no effect on cancer cell death alone, but markedly enhanced TSA-induced cell death in a dosedependent manner in both CaOV3 and L3.6 cells.
-
Cell Line:HUVECs
-
Concentration:10 μM
-
Incubation Time:48 h
-
Result:Signifcantly increased the expression of miR29b and decreased the expressions of Akt3, PI3K and VEGFA in HUVECs.
化学情報
-
CAS 番号 124753-97-5
-
性状 Solid
-
分子量 397.63
-
分子式 C24H47NO3
-
Color White to off-white
-
SMILES
CCCCCC(N[C@@H](CO)[C@H](O)/C=C/CCCCCCCCCCCCC)=O
-
別名
C6-Cer; N-Hexanoylsphingosine
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Acta Pharm Sin B
Macrophage P2Y6R activation aggravates psoriatic inflammation through IL-27-mediated Th1 responses. [Abstract]2024 Oct;14(10):4360-4377. PMID: 39525587
C6 Ceramide purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 Oct;14(10):4360-4377. [Abstract]
IL-27 supernatant concentration of BMDMs stimulated by UDP and IMQ after PKC, JNK, p38, and ERK agonist (C6 Ceramide, 10 μmol/L) treatment.
-
Sci Total Environ
Cadmium exacerbates liver injury by remodeling ceramide metabolism: Multiomics and laboratory evidence. [Abstract]2024 May 1:923:171405. PMID: 38432385
C6 Ceramide purchased from MedChemExpress. Usage Cited in: Sci Total Environ. 2024 May 1:923:171405. [Abstract]
Cell viability of BRL-3A cells after C6 Ceramide (0-50 μM) intervention for 24 h was detected by CCK-8. Other groups were compared with 0 μM group.
C6 Ceramide purchased from MedChemExpress. Usage Cited in: Sci Total Environ. 2024 May 1:923:171405. [Abstract]
The expression levels of apoptosis-related proteins in BRL-3A cells after 25 μM C6 Ceramide intervention and/or 20 μM cadmium exposure for 24 h were detected by western blotting.
C6 Ceramide purchased from MedChemExpress. Usage Cited in: Sci Total Environ. 2024 May 1:923:171405. [Abstract]
C6 Ceramide (25 μM). Hoechst/PI double staining: Hoechst/PI was used to double stain and observe them under fluorescence microscope (200×). Hoechst 33342 can stain the nucleus with blue fluorescence. PI can stain necrotic cells with red fluorescence.
C6 Ceramide purchased from MedChemExpress. Usage Cited in: Sci Total Environ. 2024 May 1:923:171405. [Abstract]
C6 Ceramide (25 μM). The levels of oxidative stress related indicators GSH, MDA, and SOD in BRL-3A cells.
C6 Ceramide purchased from MedChemExpress. Usage Cited in: Sci Total Environ. 2024 May 1:923:171405. [Abstract]
C6 Ceramide (25 μM). ROS production was detected by DCFH-DA staining (200×).
-
Br J Pharmacol
FGF1ΔHBS ameliorates DSS-induced ulcerative colitis by reducing neutrophil recruitment through the MAPK pathway. [Abstract]2025 Apr 21. PMID: 40258390
溶剤 & 溶解度
DMSO : ≥ 100 mg/mL (251.49 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.29 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.29 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Zhu Q, et, al. C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivo. Cell Death Dis. 2011 Jan 27;2(1):e117. [Content Brief]
[2]. Liu L, et, al. C6-ceramide treatment inhibits the proangiogenic activity of multiple myeloma exosomes via the miR-29b/Akt pathway. J Transl Med. 2020 Aug 3;18(1):298. [Content Brief]
[3]. Mitoma J, et al. Bipotential roles of ceramide in the growth of hippocampal neurons: promotion of cell survival and dendritic outgrowth in dose- and developmental stage-dependent manners. J Neurosci Res. 1998 Mar 15;51(6):712-22. [Content Brief]
[4]. Flowers M, et al. C6-ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth. Breast Cancer Res Treat. 2012 Jun;133(2):447-58. [Content Brief]
[5]. Wilhelm R, et al. C6 Ceramide (d18:1/6:0) as a Novel Treatment of Cutaneous T Cell Lymphoma. Cancers (Basel). 2021 Jan 13;13(2):270. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5149 mL | 12.5745 mL | 25.1490 mL | 62.8725 mL |
| 5 mM | 0.5030 mL | 2.5149 mL | 5.0298 mL | 12.5745 mL | |
| 10 mM | 0.2515 mL | 1.2575 mL | 2.5149 mL | 6.2873 mL | |
| 15 mM | 0.1677 mL | 0.8383 mL | 1.6766 mL | 4.1915 mL | |
| 20 mM | 0.1257 mL | 0.6287 mL | 1.2575 mL | 3.1436 mL | |
| 25 mM | 0.1006 mL | 0.5030 mL | 1.0060 mL | 2.5149 mL | |
| 30 mM | 0.0838 mL | 0.4192 mL | 0.8383 mL | 2.0958 mL | |
| 40 mM | 0.0629 mL | 0.3144 mL | 0.6287 mL | 1.5718 mL | |
| 50 mM | 0.0503 mL | 0.2515 mL | 0.5030 mL | 1.2575 mL | |
| 60 mM | 0.0419 mL | 0.2096 mL | 0.4192 mL | 1.0479 mL | |
| 80 mM | 0.0314 mL | 0.1572 mL | 0.3144 mL | 0.7859 mL | |
| 100 mM | 0.0251 mL | 0.1257 mL | 0.2515 mL | 0.6287 mL |
C6 Ceramide 関連分類
HY-19542 関連分類
Powered by Bioz